Skip to content
Agentic OS
Menu

Intelligence / Healthtech / PMA Approvals / Ventana Medical Systems, INC. (Roche Tissue Diagnostics)

Approvalsdevice change approved (PMA)8 Oct 2026

Ventana Medical Systems, INC. (Roche Tissue Diagnostics)

8 Oct 2026: Device change approved (PMA) · VENTANA MMR RxDx Panel. Recorded in the openFDA device PMA data.

View the source record

Decided
8 Oct 2026
Device
VENTANA MMR RxDx Panel
Specialty
Pathology
Type
Supplement (Normal 180 Day Track)
Reason
Change Design/Components/Specifications/Material
Reference
P210001 S016
Location
Tucson, AZ
What this signal means

A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.

  1. Cardiovascular leads with 53 of 120, then Pathology (15).
  2. 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Ventana Medical Systems, INC. (Roche Tissue Diagnostics)

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Ventana Medical Systems, INC. (Roche Tissue Diagnostics) in our registers.

More in Pathology

PMA Approvals

See all

Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.